Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced?
OBJECTIVE
To investigate whether a dose reduction to CT-enlarged but FDG-PET-negative (([(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography) inguinal lymph nodes in radiochemotherapy of anal cancer is safe.


METHODS
39 sequential patients with anal cancer (mean age 59 years [range: 37-86 years], median follow-up 26 months [range: 3-51 months]) receiving pretherapeutic FDG-PET were included. All patients were treated with combined radiochemotherapy including elective radiation of the inguinal lymph nodes with 36 Gy. In case of involvement (FDG-PET positivity defined as normalized SUV [standard uptake value] above Delta > 2.5 higher than blood pool), radiation dose was increased up to 50-54 Gy. Planning CT and PET results were compared for detectability and localization of lymph nodes. In addition, local control and freedom from metastases were analyzed regarding the lymph node status as determined by FDG-PET.


RESULTS
In the planning CTs, a total of 162 inguinal lymph nodes were detected with 16 in nine patients being suspicious. Only three of these lymph nodes in three patients were PET-positive receiving 50.4-54 Gy, whereas all other patients only received elective inguinal nodal irradiation. No recurrence in inguinal lymph nodes occurred, especially not in patients with CT-enlarged inguinal lymph nodes and elective irradiation only. Patients with PET-positive nodal disease had a higher risk of developing distant metastases (p = 0.045).


CONCLUSIONS
Reduction of the irradiation dose to CT-enlarged but PET-negative inguinal lymph nodes in anal cancer seems not to result in increased failure rates.
Mai
Sabine Kathrin
SK
Department of Radiation Oncology, University Medical Center Mannheim, University of Heidelberg, Germany. sabine.mai@radonk.ma.uni-heidelberg.de
Welzel
Grit
G
Hermann
Brigitte
B
Wenz
Frederik
F
Haberkorn
Uwe
U
Dinter
Dietmar Jörg
DJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001005:Anus Neoplasms / Q000175:diagnosis* / Q000532:radiotherapy*; D001822:Body Burden; D005260:Female; D019788:Fluorodeoxyglucose F18; D006119:Groin; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D011835:Radiation Protection / Q000379:methods*; D019275:Radiopharmaceuticals; D020266:Radiotherapy, Conformal / Q000379:methods*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18